Annals of Oncology Advance Access originally published online on January 19, 2006
Annals of Oncology 2006 17(4):614-622; doi:10.1093/annonc/mdj134
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
1 Hôpital Saint Louis, Paris, France; 2 Instituto Valenciano de Oncología, Valencia, Spain; 3 Centre Hospitalier André Boulloche, Montbéliard, France; 4 Medical Oncology Centre of Rosebank, Johannesburg, South Africa; 5 Hospital Bulovka, Prague, Czech Republic
* Correspondence to: Prof. M. Marty, Institut Centre Hospitalier Universitaire Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris Cedex, France. Tel: +33-1-42-49-48-10; Fax: +33-1-42-49-48-11; E-mail: m.marty{at}sls.aphp.fr
Background: Anthracycline-induced cardiotoxicity has led to the adoption of empirical dose limits that may restrict continued use of anthracyclines among patients who might benefit. Dexrazoxane, a cardioprotective agent, has been shown to reduce the risk of anthracycline-associated cardiotoxicity when given from first dose of anthracycline. This study sought to confirm the benefit of dexrazoxane in patients at high risk of cardiotoxicity due to prior anthracycline use.
Patients and methods: A total of 164 female breast cancer patients, previously treated with anthracyclines, received anthracycline-based chemotherapy either with (n = 85) or without (n = 79) dexrazoxane for a maximum of six cycles.
Results: Compared with those receiving anthracycline alone, patients treated with dexrazoxane experienced significantly fewer cardiac events (39% versus 13%, P < 0.001) and a lower and less severe incidence of congestive heart failure (11% versus 1%, P < 0.05). Tumor response rate was unaffected by dexrazoxane therapy. The frequency of adverse events was similar between groups and there were no significant between-group differences in the number of dose modifications/interruptions.
Conclusion: Dexrazoxane significantly reduced the occurrence and severity of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac dysfunction due to previous anthracycline treatment without compromising the antitumor efficacy of the chemotherapeutic regimen.
Key words: anthracycline, breast cancer, cardioprotection, clinical trial, dexrazoxane
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer Anthracycline Cardiotoxicity: From Bench to Bedside J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hellmann Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Evidence J. Clin. Oncol., October 10, 2007; 25(29): 4689 - 4690. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Lipshultz, S. R. Lipsitz, and E. J. Orav Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Compelling Evidence J. Clin. Oncol., July 20, 2007; 25(21): 3179 - 3179. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues Mol. Interv., June 1, 2007; 7(3): 147 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347. [Abstract] [Full Text] [PDF]
|
|